Eos SENOLYTIX, Perseus SENOLYTIX, and Phoenix SENOLYTIX are affiliated with SENOTHERAPEUTIX, Inc., d/b/a GEROTHERAPEUTIX, Inc.
Improving Healthspan, Increasing Lifespan
Targeting the Biology of Aging Itself
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, and sarcopenia along with many others. Geroscience is the field that investigates how the biological mechanisms of aging drive chronic diseases and seeks ways to create gerotherapeutics that target those mechanisms to extend healthy years of life. We are developing gerotherapeutics aimed at targeting aging’s underlying biological processes to improve healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
Like a true gerotherapeutic, our MitoXcel™ geropeptides don’t target individual diseases to achieve an improvement in healthspan, they simply target the underlying causes of aging via the mitochondria. Phenotypic healthspan improvements, like loss of fat and gain of muscle, increases in exercise capacity and improvements in cognition, along with many others that we have observed and documented, are simply the downstream effects that occur without any further intervention.
Why Trust Dr. Slawin?
Dr. Slawin’s h-index on Google Scholar — a standard metric of research impact based on citation counts — is 70. That figure is rare in medicine: full professors in medicine and the life sciences typically sit between 30 and 60, and 25 already marks a researcher above standard full-professor status. In urology, his own field, the median among department chairs and chiefs is around 26. An h-index of 70 places him among the most-cited figures in a specialty, built on more than 500 peer-reviewed papers cited over 22,000 times (Google Scholar).
That record was built in clinical practice as much as research. Dr. Slawin held the Dan Duncan Family Professorship at Baylor College of Medicine, directed the Baylor Prostate Center, and was a pioneer in robotic-assisted prostatectomy, performing more than 4,000 of those surgeries in men with prostate cancer during his career as a cancer surgeon. He is co-inventor of the Prostate Health Index (phi), an FDA-cleared diagnostic in clinical use internationally, built on his discovery of [-2]proPSA, a novel and highly specific biomarker of prostate cancer, made by melding his skills as both a “bench” researcher with his considerable experience caring for patients “at the bedside”.
In 2004, years before cellular immunotherapy gained wide acceptance, he founded Bellicum Pharmaceuticals, one of the first companies built around CAR-T — recognizing, before most others did, the role immunotherapy would play across cancer therapeutics. A decade later, the company listed on Nasdaq with the backing of leading Wall Street institutions.
His work since has turned to a larger problem: aging is a biological process that affects all of us, and biological processes can be acted upon. He now leads GEROTHERAPEUTIX, whose platform Dr. Slawin discovered, MitoXcel, is a class of geropeptides designed to act on the mitochondrial mechanisms of cellular aging, now in development to extend the years people live in good health. Once again, Dr. Slawin’s read on where medicine is headed — proven correct twice already — is pointed at aging itself.
Our Origin and Family of Companies
In 2019, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine have been spun out into three subsidiaries of SENOTHERAPEUTIX, Inc., which was registered in Texas as d/b/a GEROTHERAPEUTIX, Inc. in 2025: (1) Eos SENOLYTIX, a longevity company developing novel MitoXcel™ geropeptide therapeutics to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel MitoXcel™ oncopeptides to treat cancer via this same novel target as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them, and our MitoXcel™ Technology website, that explains the remarkable technology driving them!
